Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2011, Article ID 195831, 6 pages
http://dx.doi.org/10.1155/2011/195831
Research Article

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab

1Department of Biometrics, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA
2Neurology Clinical Development, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA
3Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA

Received 2 May 2011; Revised 17 November 2011; Accepted 19 November 2011

Academic Editor: Mamede de Carvalho

Copyright © 2011 Y. C. Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  2. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Google Scholar · View at Scopus
  3. L. D. Jacobs, D. L. Cookfair, R. A. Rudick et al., “Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis,” Annals of Neurology, vol. 39, no. 3, pp. 285–294, 1996. View at Publisher · View at Google Scholar · View at PubMed
  4. L. D. Jacobs, D. L. Cookfair, R. A. Rudick et al., “Erratum: intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis,” Annals of Neurology, vol. 40, no. 3, p. 480, 1996. View at Google Scholar
  5. P. Duquette, M. Girard, L. Despault et al., “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial,” Neurology, vol. 43, no. 4, pp. 655–661, 1993. View at Google Scholar
  6. G. C. Ebers, G. Rice, J. Lesaux et al., “Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis,” The Lancet, vol. 352, no. 9139, pp. 1498–1504, 1998. View at Publisher · View at Google Scholar
  7. G. C. Ebers, G. Rice, J. Lesaux et al., “Erratum: randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis,” The Lancet, vol. 353, no. 9153, p. 678, 1999. View at Google Scholar
  8. C. H. Polman, P. W. O'Connor, E. Havrdova et al., “A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 354, no. 9, pp. 899–910, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. R. L. Prentice, “Surrogate endpoints in clinical trials: definition and operational criteria,” Statistics in Medicine, vol. 8, no. 4, pp. 431–440, 1989. View at Google Scholar · View at Scopus
  11. M. P. Sormani, P. Bruzzi, G. Comi, and M. Filippi, “MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients,” Neurology, vol. 58, no. 3, pp. 417–421, 2002. View at Google Scholar · View at Scopus
  12. M. P. Sormani, P. Bruzzi, K. Beckmann et al., “MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b,” Neurology, vol. 60, no. 9, pp. 1462–1466, 2003. View at Google Scholar · View at Scopus
  13. M. P. Sormani, B. Stubinski, P. Cornelisse, S. Rocak, D. Li, and N. de Stefano, “Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis,” Multiple Sclerosis, vol. 17, no. 5, pp. 541–549, 2011. View at Publisher · View at Google Scholar · View at PubMed
  14. M. P. Sormani, D. Li, P. Bruzzi et al., “Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis,” Neurology, vol. 77, no. 18, pp. 1684–1690, 2001. View at Publisher · View at Google Scholar · View at PubMed
  15. L. S. Freedman, B. I. Graubard, and A. Schatzkin, “Statistical validation of intermediate endpoints for chronic diseases,” Statistics in Medicine, vol. 11, no. 2, pp. 167–178, 1992. View at Google Scholar · View at Scopus
  16. A. Alonso, G. Molenberghs, T. Burzykowski et al., “Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints,” Biometrics, vol. 60, no. 3, pp. 724–728, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at MathSciNet · View at Scopus
  17. Y. Qu and M. Case, “Quantifying the effect of the surrogate marker by information gain,” Biometrics, vol. 63, no. 3, pp. 958–963, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. M. P. Sormani, L. Bonzano, L. Roccatagliata, G. L. Mancardi, A. Uccelli, and P. Bruzzi, “Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach,” Neurology, vol. 75, no. 4, pp. 302–305, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus